The study suggests the tests could save lives by catching cancer at earlier stages, when it's more easily treated. It ...

The promise of scientific and medical innovation often comes with a downside: improvements in care benefit some people, but not all. Without concerted effort, that is exactly what could happen with ...

Gene Solutions, a pioneering genetic testing company, announced key achievements at the European Society for Medical Oncology ...

Dublin, Aug. 26, 2025 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Market Industry Trends and Global Forecasts to 2035, by Application, Target Disease Indication, Type of Circulating Biomarker, Type of ...

This regulatory approval of the Guardant360® CDx test, which identifies ESR1 mutations using a blood sample, is expected to increase targeted treatment options for patients with hormone ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA ...

DURHAM, N.C.--(BUSINESS WIRE)--GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the launch of its EXpressCT SM (Expression ...

Back in 2016, the FDA ushered in a new era by approving the first blood-based cancer-detection test, known as a “liquid biopsy,” which was made by Roche to detect EGFR mutations in non-small cell lung ...

Last December, researchers at Johns Hopkins published a study in the journal JAMA Oncology comparing two commercially available 'liquid biopsy' tests for detecting cancer from blood samples using ...

For those with cancer, precision oncology promises better treatment plans. It is about allowing treatments to be selected on the basis of genetic signatures, which can reveal specific tumorigenic ...

Two Johns Hopkins prostate cancer researchers found significant disparities when they submitted identical patient samples to two different commercial liquid biopsy providers. The results, they say, ...

Blood-based liquid biopsy tests for colorectal cancer (CRC) are in development and may soon hit the market, expanding potential options for patients who refuse traditional colonoscopy. But would they ...